PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31636311-8	2019	However, losartan only reduced CS-induced increases in IL-6 mRNA expression.	Losartan	9-17	interleukin 6	Mus musculus	55-59	
25604220-12	2014	Yet after a pretreatment of losartan, the pulmonary level of IL-6 markedly decreased.	Losartan	28-36	interleukin 6	Mus musculus	61-65	
34704526-7	2022	The expression levels of HMGB1, tumor necrosis factor-alpha and interleukin-6 in both the serum and myocardium were upregulated in response to TAC, while they were significantly reduced by losartan.	Losartan	189-197	interleukin 6	Mus musculus	64-77	
34261799-4	2021	Using NF2 mouse models, we found that losartan treatment normalized the TME by (i) reducing neuroinflammatory IL-6/STAT3 signaling and preventing hearing loss, (ii) normalizing tumor vasculature and alleviating neuro-edema, and (iii) increasing oxygen delivery and enhancing efficacy of radiation therapy.	Losartan	38-46	interleukin 6	Mus musculus	110-114	
32665776-7	2020	We found that losartan inhibited lung metastasis of CRC and there was a reduction of the IL-6 expression level in the tissue sample.	Losartan	14-22	interleukin 6	Mus musculus	89-93	
10840457-10	2000	In animals treated with losartan, kidney TGF-beta, IFN-gamma and IL-6 decreased significantly at 3 and 8 weeks as compared with controls, untreated or those treated with NaCl, (p <0.005 respectively).	Losartan	24-32	interleukin 6	Mus musculus	65-69	
34094856-11	2021	Losartan treatment or PPARgamma activation contributes to reduced levels of IL-6, IL-1beta, TNF-alpha, and COX-2, expression of TGF-beta1, MMP-13, ADAMTS-4, ADAMTS-5, HtrA1, and iNOS, along with reduced Smad2 and Smad3 phosphorylation, but elevated PPARgamma and Collagen II expression in vivo and in vitro.	Losartan	0-8	interleukin 6	Mus musculus	76-80	
31636311-10	2019	In conclusion, losartan did not inhibit CS-induced BALF cellularity despite reducing whole lung IL-6 mRNA and Ang-II receptor expression.	Losartan	15-23	interleukin 6	Mus musculus	96-100	
26194911-7	2015	In line with this, losartan reduced inflammation and diminished TNF-alpha and IL-6 expression in injured forepaws.	Losartan	19-27	interleukin 6	Mus musculus	78-82	
27997528-8	2017	Furthermore, interleukin (IL)-6 mRNA was markedly attenuated by IVIG+losartan.	Losartan	69-77	interleukin 6	Mus musculus	13-31	
25988231-8	2015	Losartan treatment prevented tumor-induced loss of muscle mass and in vitro c26 cell proliferation, decreased tumor weight, and attenuated myocardial expression of interleukin-6.	Losartan	0-8	interleukin 6	Mus musculus	164-177	
18827741-10	2009	Losartan treatment significantly attenuated TNF-alpha, IL-6, and IL-1beta 6 h after CLP.	Losartan	0-8	interleukin 6	Mus musculus	55-59	
23647130-9	2013	Losartan attenuated the increased serum alanine aminotransferase activity, TNF-alpha and IL-6 levels, and nuclear concentrations of NF-kappaB in I/R.	Losartan	0-8	interleukin 6	Mus musculus	89-93	
25567153-9	2014	(3) The levels of IL-6 in lung tissue were significantly enhanced in the LPS-induced ALI mice, while it markedly decreased in ALI +losartan group.	Losartan	131-139	interleukin 6	Mus musculus	18-22	
21109230-11	2011	However, these effects were abolished by pre-treatment with Ang II type 1 (AT1) receptor antagonist, losartan, and the ERK1/2 inhibitor, U0126, inhibited Ang II-mediated IL-6 expression and the phosphorylation of ERK1/2.	Losartan	101-109	interleukin 6	Mus musculus	170-174	
21479465-8	2008	As both telmisartan and losartan attenuated interleukin-6 mRNA expression in the aorta, there was a significant change in endothelial nitric oxide synthase (eNOS) mRNA in the aorta.	Losartan	24-32	interleukin 6	Mus musculus	44-57